Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSamantha ShenoyJWJeffrey L. WolfTMThomas G. Martin

Discussion

Loading...

Member takes

Overview

Analysis reveals median progression-free survival of 17.1 months in multiple myeloma patients receiving bispecific antibody therapy, suggesting treatment efficacy amidst high-risk profiles.

Key Points

  • Patients receiving bispecific antibody therapy achieved a median progression-free survival of 17.1 months, highlighting treatment efficiency.
  • The overall response rate was 81% for first therapy, maintaining significant outcomes even in relapsed cases amidst high-risk symptoms.
  • Retrospective analysis at a single institution assessed treatment impacts across various cytokines and clinical features linking therapies and patient survival.
  • C-reactive protein levels correlated with adverse prognosis in patients, indicating necessary monitoring in managing multiple myeloma therapies.

Cite This Study

Shenoy et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e014https://doi.org/10.1182/blood-2025-5760
View Full Paper
Ask AI
Bookmark
Share